Literature DB >> 11898562

Evidence basis for treatment of spasticity.

D M Dawson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11898562     DOI： 10.1007/s11910-001-0051-5

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


× No keyword cloud information.
  30 in total

1.  Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study.

Authors:  G Ochs; A Struppler; B A Meyerson; B Linderoth; J Gybels; B P Gardner; P Teddy; A Jamous; P Weinmann
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-08       Impact factor: 10.154

2.  Effect on ambulation of continuous intrathecal baclofen infusion.

Authors:  P C Gerszten; A L Albright; M J Barry
Journal:  Pediatr Neurosurg       Date:  1997-07       Impact factor: 1.162

3.  The effect of dantrolene sodium on spasticity in multiple sclerosis.

Authors:  A J Gelenberg; D C Poskanzer
Journal:  Neurology       Date:  1973-12       Impact factor: 9.910

4.  A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.

Authors:  C Smolenski; S Muff; S Smolenski-Kautz
Journal:  Curr Med Res Opin       Date:  1981       Impact factor: 2.580

5.  The antispastic effects of Ba 34647 (B-4-p-chlorophenyl-gamma-amino-butyric acid) a GABA derivative.

Authors:  Y D Lapierre; R Elie; L Tetreault
Journal:  Curr Ther Res Clin Exp       Date:  1974-10

6.  Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis.

Authors:  B A Sachais; J N Logue; M S Carey
Journal:  Arch Neurol       Date:  1977-07

7.  Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group.

Authors:  C Smith; G Birnbaum; J L Carter; J Greenstein; F D Lublin
Journal:  Neurology       Date:  1994-11       Impact factor: 9.910

8.  Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study.

Authors:  R G Feldman; M Kelly-Hayes; J P Conomy; J M Foley
Journal:  Neurology       Date:  1978-11       Impact factor: 9.910

9.  Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis.

Authors:  S P Brar; M B Smith; L M Nelson; G M Franklin; N D Cobble
Journal:  Arch Phys Med Rehabil       Date:  1991-03       Impact factor: 3.966

10.  Cannabinoids control spasticity and tremor in a multiple sclerosis model.

Authors:  D Baker; G Pryce; J L Croxford; P Brown; R G Pertwee; J W Huffman; L Layward
Journal:  Nature       Date:  2000-03-02       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.